.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,956,027

« Back to Dashboard

Claims for Patent: 6,956,027

Title: N-terminally chemically modified protein compositions and methods
Abstract:Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.
Inventor(s): Kinstler; Olaf B. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:10/264,846
Patent Claims: 1. An antiviral, pegylated consensus interferon.

2. The antiviral, pegylated consensus interferon of claim 1 that is an anti-hepatitis viral, pegylated consensus interferon.

3. The antiviral, pegylated consensus interferon of claim 1 that is an antihepatitis C viral, pegylated consensus interferon.

4. The anti-hepatitis C viral, pegylated consensus interferon of claim 3 wherein said consensus interferon is selected from from the group consisting of IFN-con.sub.1, IFN-con.sub.2, and IFN-con.sub.3.

5. The anti-hepatitis C viral, pegylated consensus interferon of claim 4 wherein said consensus interferon is IFN-con.sub.1.

6. The anti-hepatitis C viral, pegylated consensus interferon of claim 4 wherein said consensus interferon is IFN-con.sub.2.

7. The anti-hepatitis C viral, pegylated consensus interferon of claim 4 wherein said consensus interferon is IFN-con.sub.3.

8. The antiviral, pegylated consensus interferon of claim 1 that is an antiviral, monopegylated consensus interferon.

9. N-terminally pegylated consensus interferon.

10. N-terminally pegylated consensus interferon of claim 9 wherein said consensus interferon is selected from the group consisting of IFN-con.sub.1, IFN-con.sub.2, and IFN-con.sub.3.

11. N-terminally pegylated consensus interferon of claim 10 wherein said consensus interferon is IFN-con.sub.1.

12. N-terminally pegylated consensus interferon of claim 10 wherein said consensus interferon is IFN-con.sub.2.

13. N-terminally pegylated consensus interferon of claim 10 wherein said consensus interferon is IFN-con.sub.3.

14. N-terminally monopegylated consensus interferon.

15. A pharmaceutical composition comprising: (a) antiviral, pegylated consensus interferon; and (b) a pharmaceutically acceptable diluent, adjuvant or carrier.

16. The pharmaceutical composition of claim 15 that is essentially free of consensus interferon PEGylated at sites other than the N-terminus.

17. The pharmaceutical composition of claim 15 werein said consensus interferon is selected from the group consisting of IFN-con.sub.1, IFN-con.sub.2, and IFN-con.sub.3.

18. The pharmaceutical composition of claim 17 wherein said consensus interferon is IFN-con.sub.1.

19. The pharmaceutical composition of claim 17 wherein said consensus interferon is IFN-con.sub.2.

20. The pharmaceutical composition of claim 17 wherein said consensus interferon is IFN-con.sub.3.

21. The pharmaceutical composition of claim 15 wherein said consensus interferon is monopegylated.

22. A pharmaceutical composition comprising: (a) N-terminally pegylated consensus interferon; and (b) a pharmaceutically acceptable diluent, adjuvant or carrier.

23. The pharmaceutical composition of claim 22 that is essentially free of consensus interferon PEGylated at sites other than the N-terminus.

24. The pharmaceutical composition of claim 22 wherein said consensus interferon is selected from the group consisting of IFN-con.sub.1, IFN-con.sub.2, and IFN-con.sub.3.

25. The pharmaceutical composition of claim 24 wherein said consensus interferon is IFN-con.sub.1.

26. The pharmaceutical composition of claim 24 wherein said consensus interferon is IFN-con.sub.2.

27. The pharmaceutical composition of claim 24 wherein said consensus interferon is IFN-con.sub.3.

28. The pharmaceutical composition of claim 25 wherein said consensus interferon is monopegylated.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc